Survey of recent breakthroughs targeting previously 'undruggable' cancer proteins and how new strategies and AI accelerate discovery and trials.
Key Takeaways
- Global trial showed daraxonrasib patients lived median 13.2 months versus 6.6 months
- Daraxonrasib targets RAS by binding a folding partner to inactivate all three family members
- AI screens identified 83 chemical candidates against mutant p53, with H3 suppressing tumors in mice